专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4382768A Apparatus for making dough envelopes containing filling 失效
标题翻译：用于制作含有填充物的面包信封的装置
公开(公告)号：US4382768A
公开(公告)日：1983-05-10
申请号：US201224
申请日：1980-10-27
申请人： Igor Lifshitz , Mikhail Kirakuperman
发明人： Igor Lifshitz , Mikhail Kirakuperman
IPC分类号： A21C9/06 , A23L1/16 , B29C1/00
CPC分类号： A21C9/068 , A21C9/06
摘要： An improved apparatus for making dough envelopes containing filling. The apparatus is molded from plastic and includes a frame structure having a plurality of interconnected hexagonal molds so as to form a honeycomb type structure. Each hexagonal mold includes six inclined cutting edges which are connected around a central inverted conical chamber. The inverted conical chamber partially supports the dough envelope during formation to produce uniformly shaped and aesthetically pleasing envelopes. Further, horizontal pasting faces are provided in the corners of each mold between the conical chamber base and cutting edges lower edges. These horizontal pasting faces in combination with the cutting edges provide a strong and uniform seal around the dough envelope edges.
摘要翻译：一种用于制作含有填充物的面团信封的改进的装置。该设备由塑料模制而成，并且包括具有多个相互连接的六角形模具以形成蜂窝型结构的框架结构。每个六角形模具包括六个倾斜的切割边缘，其围绕中心的倒圆锥形室连接。倒置的锥形室在形成期间部分地支撑面包，以产生均匀的形状和美观的包络。此外，在锥形室底座和切割边缘下边缘之间的每个模具的角部设置水平粘贴面。这些水平粘贴面与切割边缘组合提供围绕面包边缘的强而均匀的密封。

2. 发明申请

US20060205683A1 Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same 审中-公开
公开(公告)号：US20060205683A1
公开(公告)日：2006-09-14
申请号：US11432983
申请日：2006-05-11
申请人： Ilya Avrutov , Igor Lifshitz , Elizabeth Lewiner
发明人： Ilya Avrutov , Igor Lifshitz , Elizabeth Lewiner
IPC分类号： A61K31/7048 , C07H17/08
CPC分类号： C07H17/08 , C07F7/1892
摘要： The present invention relates to processes for preparing protected silylated clarithromycin oxime, preferably 6-O-methyl-2′, 4″-bis(trimethylsilyl)-erythromycin A 9-O-(2-methoxyprop-2-yl)oxime (“S-MOP oxime”), and for converting protected silylated clarithromycin oxime, preferably S-MOP oxime, to clarithromycin. Processes for preparing protected silylated clarithromycin oxime according to the present invention, include reacting a silyl oxime derivative with methylating agent in the presence of at least one solvent and a base, where the solvent comprises methyl tertbutyl ether. Processes for converting protected silylated clarithromycin oxime to clarithromycin according to the present invention, include reacting protected silylated clarithromycin oxime with ethanol and water at an ethanol to water ratio of about 1:1, in the presence of an acid and a deoximating agent and cooling the reaction mixture prior to adding sodium hydroxide, where the process takes place without any additional water addition. Further processes for converting protected silylated clarithromycin oxime to clarithromycin, include heating a mixture of protected silylated clarithromycin oxime, acid, and deoximating agent in an ethanol/water solvent to reflux for more than 4 hours, with a two-fold addition of deoximating agent to produce essentially oxime-free clarithromycin.

3. 发明授权

US07358360B2 Risedronate sodium having a very low content of iron 失效
标题翻译：利塞膦酸钠具有非常低的铁含量
公开(公告)号：US07358360B2
公开(公告)日：2008-04-15
申请号：US10759919
申请日：2004-01-16
申请人： Revital Lifshitz-Liron , Ramiy Lidor-Hadas , Nissm Sasson , Igor Lifshitz
发明人： Revital Lifshitz-Liron , Ramiy Lidor-Hadas , Nissm Sasson , Igor Lifshitz
IPC分类号： C07F9/28
CPC分类号： C07F9/59
摘要： The present invention relates to a method of making risedronate sodium substantially free of iron including the steps of refluxing, especially with mechanical agitation, a combination of risedronic acid, a sodium base, especially sodium hydroxide, and an iron-reducing amount of EDTA in a liquid that is water, a lower alkanol, or, especially, a mixture of a lower alkanol and water; and isolating risedronate sodium substantially free of iron from the combination.
摘要翻译：本发明涉及一种制备基本上不含铁的利塞膦酸钠的方法，包括以下步骤：特别是机械搅拌下，将利塞膦酸，钠碱，特别是氢氧化钠和减铁量的EDTA的组合在液体是水，低级链烷醇，或特别是低级链烷醇和水的混合物; 并从该组合中分离出基本上不含铁的利塞膦酸钠。

4. 发明授权

US06617436B2 Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same 失效
标题翻译：用于制备克拉霉素和克拉霉素中间体，基本上不含肟的克拉霉素的方法和包含其的药物组合物
公开(公告)号：US06617436B2
公开(公告)日：2003-09-09
申请号：US09736447
申请日：2000-12-15
申请人： Iiya Avrutov , Igor Lifshitz , Elizabeth Lewiner
发明人： Iiya Avrutov , Igor Lifshitz , Elizabeth Lewiner
IPC分类号： C07H100
CPC分类号： C07H17/08 , C07F7/1892
摘要： The present invention relates to processes for preparing protected silylated clarithromycin oxime, preferably 6-O-methyl-2′, 4″-bis(trimethylsilyl)-erythromycin A 9-O-(2-methoxyprop-2-yl)oxime (“S-MOP oxime”), and for converting protected silylated clarithromycin oxime, preferably S-MOP oxime, to clarithromycin. Processes for preparing protected silylated clarithromycin oxime according to the present invention, include reacting a silyl oxime derivative with methylating agent in the presence of at least one solvent and a base, where the solvent comprises methyl tertbutyl ether. Processes for converting protected silylated clarithromycin oxime to clarithromycin according to the present invention, include reacting protected silylated clarithromycin oxime with ethanol and water at an ethanol to water ratio of about 1:1, in the presence of an acid and a deoximating agent and cooling the reaction mixture prior to adding sodium hydroxide, where the process takes place without any additional water addition. Further processes for converting protected silylated clarithromycin oxime to clarithromycin, include heating a mixture of protected silylated clarithromycin oxime, acid, and deoximating agent in an ethanol/water solvent to reflux for more than 4 hours, with a two-fold addition of deoximating agent to produce essentially oxime-free clarithromycin.
摘要翻译：本发明涉及制备受保护的甲硅烷基化克拉霉素肟，优选6-O-甲基-2'，4“ - 双（三甲基甲硅烷基） - 红霉素A 9-O-（2-甲氧基丙-2-基）肟（” S-MOP肟“），并将保护的甲硅烷基化克拉霉素肟（优选S-MOP肟）转化为克拉霉素。根据本发明的制备受保护的甲硅烷基化克拉霉素肟的方法包括使甲硅烷基肟衍生物与甲基化剂在至少一种溶剂和碱的存在下反应，其中溶剂包括甲基叔丁基醚。将受保护的甲硅烷基化克拉霉素肟转化为克拉霉素的方法包括在酸和脱肟剂的存在下，将保护的甲硅烷基化克拉霉素肟与乙醇和水以约1:1的乙醇与水反应并冷却在加入氢氧化钠之前的反应混合物，其中该方法进行而没有任何额外的水添加。将受保护的甲硅烷基化克拉霉素肟转化为克拉霉素的其它方法包括在乙醇/水溶剂中将受保护的甲硅烷基化克拉霉素肟，酸和脱肟剂的混合物加热回流4小时以上，加入二肟剂至产生基本上无肟的克拉霉素。

5. 发明授权

US07671071B2 Polymorphic Form XVI of fexofenadine hydrochloride 失效
标题翻译：盐酸非索非那定的多形态XVI
公开(公告)号：US07671071B2
公开(公告)日：2010-03-02
申请号：US11243496
申请日：2005-10-03
申请人： Barnaba Krochmal , Dov Diller , Ben-Zion Dolitzky , Judith Aronhime , Shlomit Wizel , Boaz Gome , Igor Lifshitz
发明人： Barnaba Krochmal , Dov Diller , Ben-Zion Dolitzky , Judith Aronhime , Shlomit Wizel , Boaz Gome , Igor Lifshitz
IPC分类号： A61K31/445 , C07D211/22
CPC分类号： C07D211/22
摘要： Provided is a crystalline (polymorphic) form of fexofenadine hydrochloride, denominated fexofenadine hydrochloride Form XVI.
摘要翻译：提供盐酸非索非那定的结晶（多晶型）形式，称为盐酸非索非那定形式XVI。

6. 发明申请

US20090054486A1 POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE 审中-公开
标题翻译： FEXOFENADINE HYDROCHLORIDE的多晶型XVI
公开(公告)号：US20090054486A1
公开(公告)日：2009-02-26
申请号：US12208768
申请日：2008-09-11
申请人： Barnaba Krochmal , Dov Diller , Ben-Zion Dolitzky , Judith Aronhime , Shlomit Wizel , Boaz Gome , Igor Lifshitz
发明人： Barnaba Krochmal , Dov Diller , Ben-Zion Dolitzky , Judith Aronhime , Shlomit Wizel , Boaz Gome , Igor Lifshitz
IPC分类号： A61K31/445
CPC分类号： C07D211/22
摘要： Provided is a crystalline (polymorphic) form of fexofenadine hydrochloride, denominated fexofenadine hydrochloride Form XVI.
摘要翻译：提供盐酸非索非那定的结晶（多晶型）形式，称为盐酸非索非那定形式XVI。

7. 发明授权

US06350870B2 Process for preparing pure crystalline lorazepam 失效
标题翻译：制备纯结晶劳拉西泮的方法
公开(公告)号：US06350870B2
公开(公告)日：2002-02-26
申请号：US09799318
申请日：2001-03-05
申请人： Igor Lifshitz
发明人： Igor Lifshitz
IPC分类号： C07D24324
CPC分类号： C07D243/24
摘要： The present invention provides a process for preparing crystalline lorazepam substantially free of bound solvent from a lorazepam alcohol solvate or hydrate by suspending the lorazepam solvate in an organic medium selected from ethyl acetate, cyclohexane, dichloromethane, toluene and mixtures thereof. This process is useful in producing the anti-anxiety and sedative agent lorazepam in increased yields. A process for converting lorazepam lower alcohol solvates to lorazepam hydrate is also disclosed.
摘要翻译：本发明提供了一种通过将劳拉西泮溶剂化物悬浮在选自乙酸乙酯，环己烷，二氯甲烷，甲苯及其混合物的有机介质中来制备基本上不含结合的溶剂的劳拉西泮醇溶剂化物或水合物的结晶性劳拉西泮的方法。该方法可用于产生抗焦虑和镇静剂劳拉西泮的产量增加。还公开了将劳拉西泮低级醇溶剂化物转化为水合氯雷他平的方法。

8. 发明授权

US4362497A Food press form 失效
标题翻译：食品新闻形式
公开(公告)号：US4362497A
公开(公告)日：1982-12-07
申请号：US293513
申请日：1981-08-14
申请人： Igor Lifshitz
发明人： Igor Lifshitz
IPC分类号： A21C11/00 , A21C11/10 , B29C1/00
CPC分类号： A21C11/106 , A21C11/00
摘要： Food products are processed prior to consumption in a press form having multiple, separate, pre-selected planar food product molds, each having tapered walls, providing easy food product removal. The food products can have pastry dough exteriors and can be filled with selected food fillings held in position and shaped by dough crust exteriors. Multiple press form food product molds have regular planar shapes disposed multiple in a tray. One face of each product mold has a cutting-edge knife disposed thereon, conforming to the mold interior shape. The cutting-edge knife can be disposed at either mold wall taper terminus. A cooperatively shaped, one-piece negative pusher plug mold, sized to intercept each one of the multiple food product molds disposed in the tray, is used to cooperatively push each food product out of the molds in the tray simultaneously. Additional, easily insertable and removable partitions of single and double cross-wise edge-knife units can be disposed in the molds, further dividing the food products.
摘要翻译：食品在消费之前被加工成具有多个分开的，预选的平面食品模具的压榨形式，每个模具具有锥形壁，从而提供容易的食品移除。食品可以有糕点面团外观，并且可以填充保持在适当位置的选定的食物馅料，并通过面外皮成型。多重冲压成型食品模具在托盘中具有多个布置的规则的平面形状。每个产品模具的一个面具有设置在其上的切割刀，符合模具内部形状。前刀可以设置在任何一个模具壁锥形终点。用于协调地设置成拦截设置在托盘中的多个食品模具中的每一个的协同成形的单件式负推塞模具用于将每个食品同时推出托盘中的模具。另外，可以在模具中设置单个和两个交叉边缘刀单元的容易插入和移除的隔板，进一步分割食品。

9. 发明申请

US20070043099A1 Crystalline forms of carvedilol and processes for their preparation 审中-公开
标题翻译：卡维地洛的结晶形式及其制备方法
公开(公告)号：US20070043099A1
公开(公告)日：2007-02-22
申请号：US11450699
申请日：2006-06-09
申请人： Igor Lifshitz , Shlomit Wizel
发明人： Igor Lifshitz , Shlomit Wizel
IPC分类号： A61K31/403 , C07D209/82
CPC分类号： C07D209/88
摘要： This invention relates to a novel crystalline form of carvedilol, to processes for its preparation, to compositions containing it and to its use in medicine. This invention further relates to a novel process for preparing crystalline carvedilol Form II.
摘要翻译：本发明涉及一种新颖的卡维地洛结晶形式，其制备方法，含有它的组合物及其在药物中的用途。本发明还涉及制备结晶卡维地洛II型的新方法。

10. 发明申请

US20060241161A1 Process for preparing losartan potassium with improved flowability 审中-公开
标题翻译：具有改善流动性的制备氯沙坦钾的方法
公开(公告)号：US20060241161A1
公开(公告)日：2006-10-26
申请号：US11404368
申请日：2006-04-13
申请人： Igor Lifshitz , Ilan Kor , Shalom Shabat
发明人： Igor Lifshitz , Ilan Kor , Shalom Shabat
IPC分类号： A61K31/4178 , C07D403/02
CPC分类号： C07D403/10 , A61K31/4178
摘要： Provided is a method of improving the flowability of losartan potassium powder having an initial Hausner ratio of 1.45 or more, which method includes reslurrying the losatrtan potassium in a reslurry solvent.
摘要翻译：提供一种提高初始Haasner比为1.45以上的氯沙坦钾粉末的流动性的方法，该方法包括在再浆化溶剂中重新洗脱氯化钾。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式